| Net Cash Provided by (Used in) Operating Activities |
$26,586 |
USD |
78% |
Q3 2024 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$20,766 |
USD |
-83% |
Q3 2024 |
Q1 2025 |
| Common Stock, Shares Authorized |
250,000,000 |
shares |
0% |
Q1 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
125,224,373 |
shares |
24% |
Q1 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q1 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$5,820 |
USD |
-219% |
Q3 2024 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$0 |
USD |
-100% |
Q1 2025 |
Q3 2025 |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$0 |
USD |
|
Q3 2024 |
Q1 2025 |
| Deferred Tax Assets, Valuation Allowance |
$2,211,205 |
USD |
4.6% |
Q2 2024 |
FY 2023 |
| Deferred Tax Assets, Gross |
$2,211,205 |
USD |
4.6% |
Q2 2024 |
FY 2023 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$1,289,570 |
USD |
7.6% |
Q2 2024 |
FY 2023 |
| Additional Paid in Capital |
$11,139,049 |
USD |
6% |
Q1 2025 |
Q3 2025 |
| Deferred Tax Assets, Net of Valuation Allowance |
$0 |
USD |
|
Q2 2024 |
FY 2023 |